Yep, the perfect way to lure me back to a co-op survival game is by adding fishing poles and over 50...
PC Gamer· 2 days agoSurvival game Icarus launched back in December of 2021, and since then developer RocketWerkz has not...
American Society of Clinical Oncology confers highest honor upon Prof Hagop Kantarjian
WATE 6 Knoxville· 3 hours agoAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its ...
How Chinese heirloom seeds can lead to climate-adapted food for future gardeners
AZCentral | The Arizona Republic via Yahoo News· 2 days agoShe recalled a Thanksgiving dinner where they shared food from 12 different countries. "I feel food...
Intensity Therapeutics' INT230-6 Prolongs Survival Alone or in Combination With Ipilimumab in Adult...
Morningstar· 2 days agoCompared To Synthetic Controls, INT230-6 Alone Extended Survival In Refractory Soft Tissue Sarcoma Subjects by Nearly 450 Days With Favorable Safety INT230-6, a Locally Delivered ...
Opinion | What Ozempic Reveals About Desire
New York Times· 21 hours agoMs. Szalavitz is a contributing Opinion writer who covers addiction and public policy. Mary Boyer, a 41-year-old tech worker, started taking the drug...
Dog abandoned, starved in East Grand Rapids rescued by neighbors
WZZM 13 Grand Rapids· 8 hours agoA dog found abandoned and starved on a busy road in East Grand Rapids now has a glimmer of hope of ...
Drug developer Servier's brain cancer drug slows tumor progession considerably
Reuters via Yahoo News· 16 hours agoJournal of Medicine. Vorasidenib was granted fast track designation by the U.S. Food & Drug Administration (FDA) in March 2023 and the company is currently working on timelines ...
...Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6...
WPRI Providence· 18 hours agoPatients enrolled in the treatment-naïve cohort from the ongoing CHRYSALIS (NCT02609776) study had NSCLC characterized by either an EGFR exon 19 deletion (ex19del) (n=11) or L858R mutation ( ...
...Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy...
Benzinga· 19 hours agoPatients treated with dual immunotherapy-based combination demonstrate sustained clinical benefits after four years vs. chemotherapy alone, with magnitude of benefit more pronounced amongst patient subgroups with high
Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent...
FOX 5 San Diego· 19 hours agoINDIGO succeeded in meeting its primary endpoint of progression free survival (PFS) per blinded independent review committee (BIRC) and key secondary endpoint of time to next ...
Yahoo Web Search
Trending Now
